Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ARWR - Arrowhead Pharmaceuticals, Inc.
Market Cap 3.52B P/E - EPS this Y -144.30% Ern Qtrly Grth -
Income -538.64M Forward P/E -13.24 EPS next Y 10.00% 50D Avg Chg -6.00%
Sales 19.65M PEG -0.57 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 7.89 EPS next 5Y 7.33% 52W High Chg -32.00%
Recommedations 2.20 Quick Ratio 4.49 Shares Outstanding 124.32M 52W Low Chg 43.00%
Insider Own 4.47% ROA -40.72% Shares Float 110.46M Beta 0.97
Inst Own 80.46% ROE -151.84% Shares Shorted/Prior 9.05M/10.45M Price 32.97
Gross Margin 100.00% Profit Margin - Avg. Volume 906,422 Target Price 47.29
Oper. Margin -2,785.05% Earnings Date Nov 27 Volume 876,899 Change -2.11%
Healthcare | Biotechnology | United States
About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc. News
12/19/24 Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
12/11/24 Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
12/07/24 Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week
12/04/24 Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment
12/03/24 Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
12/03/24 ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
12/02/24 Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
11/30/24 Arrowhead price target lowered to $24 from $27 at Bernstein
11/29/24 Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance
11/28/24 Sarepta price target lowered to $202 from $205 at Needham
11/27/24 Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call
11/27/24 SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
11/27/24 Arrowhead Stock Rockets 16% After Major Licensing Deal
11/27/24 Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments
11/27/24 Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board
11/27/24 Arrowhead and Sarepta link for rare genetic disease treatments
11/27/24 Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ...
11/26/24 Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
11/26/24 Arrowhead Pharma, Sarepta TX ink new gene therapy deal
11/26/24 Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Sell 32.44 57,499 1,865,268 3,715,048 02/02/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Option 14.54 57,499 836,035 3,772,547 02/02/24
Hamilton James C Chief Discovery/Tran.. Chief Discovery/Trans Medicine Jan 12 Sell 36.92 7,940 293,145 210,851 01/17/24
GIVEN DOUGLAS B Director Director Jan 11 Sell 38.16 2,911 111,084 129,711 01/16/24
Waddill William D. Director Director Jan 11 Sell 38.2 3,934 150,279 47,870 01/16/24
Ferrari Mauro Director Director Jan 11 Sell 38.22 3,147 120,278 60,778 01/16/24
Vakiener Victoria Director Director Jan 11 Sell 38.36 4,720 181,059 32,001 01/16/24
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jan 04 Sell 33.89 74 2,508 136,501 01/08/24
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 04 Sell 34.89 16,104 561,869 440,600 01/08/24
San Martin Javier Chief Medical Office.. Chief Medical Officer Jan 04 Sell 34.93 8,303 290,024 198,497 01/08/24
Hamilton James C Other Other Jan 03 Sell 33.89 38,443 1,302,833 218,791 01/05/24
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 03 Sell 33.46 33,190 1,110,537 464,385 01/05/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 02 Sell 31 9,952 308,512 3,715,048 01/04/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 20 Sell 28.54 12,000 342,480 3,725,000 12/22/23
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 20 Sell 28.87 19,700 568,739 131,800 11/22/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 25 Sell 24.21 24,338 589,223 3,737,000 10/27/23
Vakiener Victoria Director Director Sep 28 Sell 26.33 1,550 40,812 21,734 10/02/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Sell 28.14 57,755 1,625,226 3,761,338 09/20/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Option 4.75 57,755 274,336 3,819,093 09/20/23
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jul 03 Sell 35.31 8,925 315,142 61,575 07/06/23
Hamilton James C Other Other Jun 30 Sell 35.53 3,000 106,590 188,484 07/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jun 27 Sell 36.20 15,000 543,000 381,704 06/29/23
GIVEN DOUGLAS B Director Director May 05 Sell 40.90 6,500 265,850 117,635 05/08/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Sell 39.38 104,928 4,132,065 3,761,338 05/05/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Option 2.01 104,928 210,905 3,811,338 05/05/23
OLUKOTUN ADEOYE Y Director Director Mar 03 Sell 32.65 11,350 370,578 7,867 03/06/23
GIVEN DOUGLAS B Director Director Feb 27 Sell 32.62 875 28,542 13,000 03/01/23
Waddill William D. Director Director Jan 09 Sell 30 3,200 96,000 28,950 01/11/23
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 05 Sell 37.39 15,000 560,850 413,375 01/06/23
Hamilton James C Other Other Jan 05 Sell 37.4 13,803 516,232 191,484 01/06/23
Hamilton James C Other Other Jan 03 Sell 39.05 10,338 403,699 145,287 01/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Dec 29 Sell 40.00 30,625 1,225,000 336,704 12/30/22
O'Brien Patrick General Counsel General Counsel Dec 21 Option 6.15 32,000 196,800 380,875 12/22/22
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 21 Sell 30.3 19,500 590,850 91,500 11/22/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 27 Option 30.99 40,624 1,258,938 3,468,314 09/29/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jul 07 Option 14.54 2,501 36,365 4,060,135 07/11/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Option 5.19 146,388 759,754 4,204,022 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Sell 51.7 146,388 7,568,260 4,057,634 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 07 Option 5.19 11,806 61,273 4,057,634 01/07/22
O'Brien Patrick General Counsel General Counsel Jan 05 Sell 62.59 32,500 2,034,175 348,875 01/07/22
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 05 Sell 62.41 40,000 2,496,400 464,005 01/06/22
Hamilton James C Other Other Jan 04 Sell 64.84 25,625 1,661,525 155,625 01/06/22
GIVEN DOUGLAS B Director Director Dec 28 Buy 66.37 655 43,472 109,868 12/29/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 68.28 60,000 4,096,800 3,219,022 12/17/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 20 Sell 65.96 65,000 4,287,400 3,279,022 10/22/21
O'Brien Patrick General Counsel General Counsel Feb 10 Option 5.22 90,000 469,800 383,375 02/10/21
O'Brien Patrick General Counsel General Counsel Feb 10 Sell 88.34 90,000 7,950,600 293,375 02/10/21
Hamilton James C Other Other Jan 15 Sell 81.4 10,000 814,000 126,250 01/15/21
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 12 Sell 81.01 13,038 1,056,208 444,005 01/12/21
O'Brien Patrick General Counsel General Counsel Jan 07 Sell 71.91 25,000 1,797,750 293,375 01/07/21